1. Home
  2. SMBC vs DBVT Comparison

SMBC vs DBVT Comparison

Compare SMBC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Missouri Bancorp Inc.

SMBC

Southern Missouri Bancorp Inc.

HOLD

Current Price

$60.35

Market Cap

613.1M

Sector

Finance

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$19.17

Market Cap

508.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMBC
DBVT
Founded
1887
2002
Country
United States
France
Employees
N/A
N/A
Industry
Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
613.1M
508.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SMBC
DBVT
Price
$60.35
$19.17
Analyst Decision
Hold
Buy
Analyst Count
4
7
Target Price
$63.63
$31.75
AVG Volume (30 Days)
52.1K
763.5K
Earning Date
01-26-2026
10-28-2025
Dividend Yield
1.52%
N/A
EPS Growth
25.22
N/A
EPS
5.46
N/A
Revenue
$178,892,000.00
$5,502,000.00
Revenue This Year
$17.66
$1,768.71
Revenue Next Year
$4.13
$1,028.88
P/E Ratio
$11.05
N/A
Revenue Growth
10.39
N/A
52 Week Low
$45.10
$2.93
52 Week High
$63.54
$26.19

Technical Indicators

Market Signals
Indicator
SMBC
DBVT
Relative Strength Index (RSI) 56.56 56.61
Support Level $61.12 $18.46
Resistance Level $63.54 $22.89
Average True Range (ATR) 1.30 1.82
MACD -0.24 0.01
Stochastic Oscillator 43.59 41.17

Price Performance

Historical Comparison
SMBC
DBVT

About SMBC Southern Missouri Bancorp Inc.

Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: